Hemostats Clinical Trial Analysis

Summary

Global Markets Direct's "Hemostats Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Hemostats manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Hemostats market categories - Hemostats
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Hemostats market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Hemostats Clinical Trials
  • 2.1 .Hemostats Clinical Trial By Equipment Type
  • 2.2 Hemostats Clinical Trials By Trial Phase and Trial Status
  • 2.3 Hemostats Pipeline Products By Development Stage
  • 2.4 Hemostats Pipeline Products By Therapy Area
  • 2.5 Hemostats Pipeline Products By News Summary
  • 2.6 Hemostats Evithrom
    • 2.6.1 A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures
  • 2.7 Hemostats Fibrin Pad
    • 2.7.1 A Prospective, Randomized, Controlled, Superiority Evaluation of Fibrin Patch as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery
  • 2.8 Hemostats ThrombiGel Paste hemostat
    • 2.8.1 Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel Versus Gelfoam-Thrombin
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Jun 17, 2009: Premier Healthcare Alliance Selects HemCon Patch
    • 3.1.2 May 05, 2009: US FDA Warns Baxter Regarding The Promotion Of Tisseel Surgical Sealant
    • 3.1.3 Feb 24, 2009: HemCon Medical Unveils Flexible Hemostatic Dressing For Clinical Settings
    • 3.1.4 Oct 09, 2008: Omrix Biopharmaceuticals Provides Update On Fibrin Pad US Phase II Clinical Trial In Mild To Moderate Bleeding
    • 3.1.5 Oct 08, 2008: Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority Of Fibrin Pad Versus SURGICEL In Mild To Moderate Bleeding In US Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
    • 3.1.6 Aug 01, 2008: Cardiva Medical Launches Boomerang Catalyst System
  • 3.2 Clinical Trials
    • 3.2.1 Oct 09, 2008: Omrix Biopharmaceuticals Provides Update On Fibrin Pad US Phase II Clinical Trial In Mild To Moderate Bleeding
    • 3.2.2 Oct 08, 2008: Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority Of Fibrin Pad Versus SURGICEL In Mild To Moderate Bleeding In US Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Hemostats Clinical Trial By Equipment Type
  • Table 2: Hemostats Clinical Trials By Trial Phase and Trial Status
  • Table 3: Hemostats Pipeline Products By Development Stage
  • Table 4: Hemostats Pipeline Products By Therapy Area
  • Table 5: Hemostats Pipeline Products By News Summary
  • Table 6: Evithrom - A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures
  • Table 7: Fibrin Pad - A Prospective, Randomized, Controlled, Superiority Evaluation of Fibrin Patch as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery
  • Table 8: ThrombiGel Paste hemostat - Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel Versus Gelfoam-Thrombin
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology